Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Jul 1;180(1):283–296. doi: 10.1084/jem.180.1.283

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

PMCID: PMC2191572  PMID: 7516410

Abstract

Psoriasis is characterized by alterations in both the epidermis and dermis of the skin. Epidermal keratinocytes display marked proliferative activation and differentiate along an "alternate" or "regenerative" pathway, while the dermis becomes infiltrated with leukocytes, particularly interleukin 2 (IL-2) receptor-bearing "activated" T cells. Psoralens, administered by the oral route, have therapeutic effects in psoriasis when photochemically activated by ultraviolet A light (PUVA therapy). Recently psoralen bath therapy has been introduced to more effectively deliver this agent to the diseased skin. We have correlated the efficacy of PUVA bath therapy with its effects on specific molecular and cellular parameters of disease, in 10 consecutive patients with recalcitrant psoriasis. Rapid clearing of lesions occurred in 8 out of 10 patients. Biopsies were taken from lesional and nonlesional skin before and after a single round of therapy, and observation was continued in our Clinical Research Center at The Rockefeller University. Enumeration of cycling keratinocytes with the Ki-67 monoclonal antibody showed that PUVA reduced cell proliferation by 73%. The pathological increase in insulin-like growth factor 1 (IGF-1) receptors was reversed, whereas epidermal growth factor (EGF) receptors, which are also increased in psoriasis, remained unchanged. Keratinocyte proteins that are expressed in abnormal sites of the epidermis during psoriasis, i.e., keratin 16, filaggrin, and involucrin, were, after PUVA treatment, localized to their normal sites. Epidermal and dermal T-lymphocytes (CD3+), as well as CD4+, CD8+, and IL-2 receptor+ subsets, were strongly suppressed by PUVA, with virtual elimination of IL-2 receptor+ T cells in some patients. Consistent with diminished lymphocyte activation, HLA-DR expression by epidermal keratinocytes was markedly reduced in treated skin. In comparison to cyclosporine treatment of psoriasis, PUVA therapy leads to more complete reversal of pathological epidermal and lymphocytic activation, changes which we propose to be the cellular basis for a more sustained remission of disease after PUVA treatment.

Full Text

The Full Text of this article is available as a PDF (2.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashworth J., Kahan M. C., Breathnach S. M. PUVA therapy decreases HLA-DR+ CDIa+ Langerhans cells and epidermal cell antigen-presenting capacity in human skin, but flow cytometrically-sorted residual HLA-DR+ CDIa+ Langerhans cells exhibit normal alloantigen-presenting function. Br J Dermatol. 1989 Mar;120(3):329–339. doi: 10.1111/j.1365-2133.1989.tb04157.x. [DOI] [PubMed] [Google Scholar]
  2. Baker B. S., Swain A. F., Fry L., Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol. 1984 May;110(5):555–564. doi: 10.1111/j.1365-2133.1984.tb04678.x. [DOI] [PubMed] [Google Scholar]
  3. Bata-Csorgo Z., Hammerberg C., Voorhees J. J., Cooper K. D. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med. 1993 Oct 1;178(4):1271–1281. doi: 10.1084/jem.178.4.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bernerd F., Magnaldo T., Darmon M. Delayed onset of epidermal differentiation in psoriasis. J Invest Dermatol. 1992 Jun;98(6):902–910. doi: 10.1111/1523-1747.ep12460344. [DOI] [PubMed] [Google Scholar]
  5. Bickers D. R. Photobiology 1937-1987. J Invest Dermatol. 1989 Apr;92(4 Suppl):25S–31S. doi: 10.1111/1523-1747.ep13074940. [DOI] [PubMed] [Google Scholar]
  6. Bos J. D., Krieg S. R. Psoriasis infiltrating cell immunophenotype: changes induced by PUVA or corticosteroid treatment in T-cell subsets, Langerhans' cells and interdigitating cells. Acta Derm Venereol. 1985;65(5):390–397. [PubMed] [Google Scholar]
  7. Bos J. D., Meinardi M. M., van Joost T., Heule F., Powles A. V., Fry L. Use of cyclosporin in psoriasis. Lancet. 1989 Dec 23;2(8678-8679):1500–1502. doi: 10.1016/s0140-6736(89)92941-3. [DOI] [PubMed] [Google Scholar]
  8. Bruno S., Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 1992 Jan;25(1):31–40. doi: 10.1111/j.1365-2184.1992.tb01435.x. [DOI] [PubMed] [Google Scholar]
  9. Burger P. M., Tijssen J. G., Suurmond D. Photochemotherapy of psoriasis. Clinical study of clearing and long-term maintenance treatment. Dermatologica. 1981;163(3):213–228. [PubMed] [Google Scholar]
  10. Collins P., Rogers S. Bath-water delivery of 8-methoxypsoralen therapy for psoriasis. Clin Exp Dermatol. 1991 May;16(3):165–167. doi: 10.1111/j.1365-2230.1991.tb00337.x. [DOI] [PubMed] [Google Scholar]
  11. Cooper K. D. Psoriasis. Leukocytes and cytokines. Dermatol Clin. 1990 Oct;8(4):737–745. [PubMed] [Google Scholar]
  12. Czernielewski J., Juhlin L., Shroot S., Brun P. Langerhans' cells in patients with psoriasis: effect of treatment with PUVA, PUVA bath, etretinate and anthralin. Acta Derm Venereol. 1985;65(2):97–101. [PubMed] [Google Scholar]
  13. Elder J. T., Fisher G. J., Lindquist P. B., Bennett G. L., Pittelkow M. R., Coffey R. J., Jr, Ellingsworth L., Derynck R., Voorhees J. J. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science. 1989 Feb 10;243(4892):811–814. doi: 10.1126/science.2916128. [DOI] [PubMed] [Google Scholar]
  14. Ellis C. N., Fradin M. S., Messana J. M., Brown M. D., Siegel M. T., Hartley A. H., Rocher L. L., Wheeler S., Hamilton T. A., Parish T. G. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991 Jan 31;324(5):277–284. doi: 10.1056/NEJM199101313240501. [DOI] [PubMed] [Google Scholar]
  15. Fry L. The role of the T cell in psoriasis and the action of cyclosporin in this disease. Acta Derm Venereol Suppl (Stockh) 1989;146:133–135. [PubMed] [Google Scholar]
  16. Gommans J. M., van Hezik S. J., van Huystee B. E. Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVA and methotrexate therapy. Br J Dermatol. 1987 May;116(5):661–666. doi: 10.1111/j.1365-2133.1987.tb05899.x. [DOI] [PubMed] [Google Scholar]
  17. Gottlieb A. B., Chang C. K., Posnett D. N., Fanelli B., Tam J. P. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med. 1988 Feb 1;167(2):670–675. doi: 10.1084/jem.167.2.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gottlieb A. B., Grossman R. M., Khandke L., Carter D. M., Sehgal P. B., Fu S. M., Granelli-Piperno A., Rivas M., Barazani L., Krueger J. G. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302–309. doi: 10.1111/1523-1747.ep12499782. [DOI] [PubMed] [Google Scholar]
  19. Gottlieb A. B., Lifshitz B., Fu S. M., Staiano-Coico L., Wang C. Y., Carter D. M. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med. 1986 Oct 1;164(4):1013–1028. doi: 10.1084/jem.164.4.1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gottlieb A. B., Luster A. D., Posnett D. N., Carter D. M. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med. 1988 Sep 1;168(3):941–948. doi: 10.1084/jem.168.3.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Grossman R. M., Krueger J., Yourish D., Granelli-Piperno A., Murphy D. P., May L. T., Kupper T. S., Sehgal P. B., Gottlieb A. B. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6367–6371. doi: 10.1073/pnas.86.16.6367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gupta A. K., Anderson T. F. Psoralen photochemotherapy. J Am Acad Dermatol. 1987 Nov;17(5 Pt 1):703–734. doi: 10.1016/s0190-9622(87)70255-2. [DOI] [PubMed] [Google Scholar]
  23. Hammer R. E., Maika S. D., Richardson J. A., Tang J. P., Taurog J. D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990 Nov 30;63(5):1099–1112. doi: 10.1016/0092-8674(90)90512-d. [DOI] [PubMed] [Google Scholar]
  24. Hancock G. E., Kaplan G., Cohn Z. A. Keratinocyte growth regulation by the products of immune cells. J Exp Med. 1988 Oct 1;168(4):1395–1402. doi: 10.1084/jem.168.4.1395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Huuskonen H., Koulu L., Wilén G. Quantitative determination of methoxsalen in human serum, suction blister fluid and epidermis by gas chromatography mass spectrometry. Photodermatol. 1984 Jun;1(3):137–140. [PubMed] [Google Scholar]
  26. Khandke L., Krane J. F., Ashinoff R., Staiano-Coico L., Granelli-Piperno A., Luster A. D., Carter D. M., Krueger J. G., Gottlieb A. B. Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways. Arch Dermatol. 1991 Aug;127(8):1172–1179. doi: 10.1001/archderm.127.8.1172. [DOI] [PubMed] [Google Scholar]
  27. Koulu L. M., Jansén C. T. Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. Comparison of 8-methoxypsoralen and trimethylpsoralen photosensitization. J Am Acad Dermatol. 1988 May;18(5 Pt 1):1053–1059. doi: 10.1016/s0190-9622(88)70104-8. [DOI] [PubMed] [Google Scholar]
  28. Koulu L., Söderström K. O., Jansén C. T. Relation of antipsoriatic and Langerhans cell depleting effects of systemic psoralen photochemotherapy: a clinical, enzyme histochemical, and electron microscopic study. J Invest Dermatol. 1984 Jun;82(6):591–593. doi: 10.1111/1523-1747.ep12261358. [DOI] [PubMed] [Google Scholar]
  29. Krane J. F., Gottlieb A. B., Carter D. M., Krueger J. G. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med. 1992 Apr 1;175(4):1081–1090. doi: 10.1084/jem.175.4.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Krane J. F., Murphy D. P., Carter D. M., Krueger J. G. Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor I/somatomedin C (IGF-I) on keratinocyte proliferation may be mediated by IGF-I transmodulation of the EGF receptor. J Invest Dermatol. 1991 Apr;96(4):419–424. doi: 10.1111/1523-1747.ep12469799. [DOI] [PubMed] [Google Scholar]
  31. Krueger J. G., Krane J. F., Carter D. M., Gottlieb A. B. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol. 1990 Jun;94(6 Suppl):135S–140S. doi: 10.1111/1523-1747.ep12876121. [DOI] [PubMed] [Google Scholar]
  32. Krüger J., Christophers E., Schlaak M. Dose-effects of 8-methoxypsoralen and UVA in cultured human lymphocytes. Br J Dermatol. 1978 Feb;98(2):141–144. doi: 10.1111/j.1365-2133.1978.tb01614.x. [DOI] [PubMed] [Google Scholar]
  33. Kupper T. S. Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations. J Clin Invest. 1990 Dec;86(6):1783–1789. doi: 10.1172/JCI114907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lindelöf B., Sigurgeirsson B., Tegner E., Larkö O., Berne B. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report. Arch Dermatol. 1992 Oct;128(10):1341–1344. doi: 10.1001/archderm.1992.01680200051005. [DOI] [PubMed] [Google Scholar]
  35. Lisby S., Ralfkiaer E., Rothlein R., Vejlsgaard G. L. Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation. Br J Dermatol. 1989 Apr;120(4):479–484. doi: 10.1111/j.1365-2133.1989.tb01320.x. [DOI] [PubMed] [Google Scholar]
  36. Lowe N. J., Weingarten D., Bourget T., Moy L. S. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J Am Acad Dermatol. 1986 May;14(5 Pt 1):754–760. doi: 10.1016/s0190-9622(86)70089-3. [DOI] [PubMed] [Google Scholar]
  37. Mansbridge J. N., Knapp A. M. Changes in keratinocyte maturation during wound healing. J Invest Dermatol. 1987 Sep;89(3):253–263. doi: 10.1111/1523-1747.ep12471216. [DOI] [PubMed] [Google Scholar]
  38. Nanney L. B., Stoscheck C. M., Magid M., King L. E., Jr Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol. 1986 Mar;86(3):260–265. doi: 10.1111/1523-1747.ep12285389. [DOI] [PubMed] [Google Scholar]
  39. Nickoloff B. J. The cytokine network in psoriasis. Arch Dermatol. 1991 Jun;127(6):871–884. [PubMed] [Google Scholar]
  40. Petzelbauer P., Stingl G., Wolff K., Volc-Platzer B. Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol. 1991 Mar;96(3):362–369. doi: 10.1111/1523-1747.ep12465404. [DOI] [PubMed] [Google Scholar]
  41. Singer K. H., Tuck D. T., Sampson H. A., Hall R. P. Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses. J Invest Dermatol. 1989 May;92(5):746–750. doi: 10.1111/1523-1747.ep12722441. [DOI] [PubMed] [Google Scholar]
  42. Smoller B. A., McNutt N. S., Carter D. M., Gottlieb A. B., Hsu A., Krueger J. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis. Arch Dermatol. 1990 Jan;126(1):78–83. [PubMed] [Google Scholar]
  43. Turksen K., Kupper T., Degenstein L., Williams I., Fuchs E. Interleukin 6: insights to its function in skin by overexpression in transgenic mice. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5068–5072. doi: 10.1073/pnas.89.11.5068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Vassar R., Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev. 1991 May;5(5):714–727. doi: 10.1101/gad.5.5.714. [DOI] [PubMed] [Google Scholar]
  45. Weinstein G. D., Frost P. Abnormal cell proliferation in psoriasis. J Invest Dermatol. 1968 Mar;50(3):254–259. [PubMed] [Google Scholar]
  46. Weiss R. A., Guillet G. Y., Freedberg I. M., Farmer E. R., Small E. A., Weiss M. M., Sun T. T. The use of monoclonal antibody to keratin in human epidermal disease: alterations in immunohistochemical staining pattern. J Invest Dermatol. 1983 Sep;81(3):224–230. doi: 10.1111/1523-1747.ep12518198. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES